NAD takes issue with University Medical
This article was originally published in The Tan Sheet
Executive SummaryThe National Advertising Division recommends University Medical Pharmaceuticals discontinue claims that compare the effects of its WrinkleFree Eyes to those of Botox, the Council of Better Business Bureaus division says Aug. 19. NAD says the firm should discontinue claims such as, "Clinically proven to reduce wrinkle appearance up to 85 percent in only 20 minutes" and "Truly effective topical alternative to Botox" because of a lack of evidence. NAD asks that the firm remove before-and-after photographs because the lighting, posing and cosmetic application are different in the first photo. The firm said the photos are not misleading. The Irvine, Calif., firm said it is disappointed with NAD's decision, but will consider the recommendations and modify its advertising accordingly
You may also be interested in...
While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.
Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.